Problem: Patents have been criticized in the developing world, as they are thought to reduce access to existing medicines. Reconciling patents and universal access to medicine would require an efficient international policy of price discrimination. Moreover, under the TRIPS agreement of the World Trade Organization, countries must allow pharmaceutical products to be patented. In 2001, the WTO adopted the Doha Declaration, which indicates that the TRIPS agreement should be read with the goals of public health in mind, and allows some methods for circumventing pharmaceutical monopolies: via compulsory licensing or parallel imports, even before patent expiration.
The Doha Declaration allows for what ways for monopolies to be bypassed?
---
Answer: compulsory licensing or parallel imports

Problem: In 1238, King James I of Aragon, with an army composed of Aragonese, Catalans, Navarrese and crusaders from the Order of Calatrava, laid siege to Valencia and on 28 September obtained a surrender. Fifty thousand Moors were forced to leave. Poets such as Ibn al-Abbar and Ibn Amira mourned this exile from their beloved Valencia. After the Christian victory and the expulsion of the Muslim population the city was divided between those who had participated in the conquest, according to the testimony in the Llibre del Repartiment (Book of Distribution). James I granted the city new charters of law, the Furs of Valencia, which later were extended to the whole kingdom of Valencia. Thenceforth the city entered a new historical stage in which a new society and a new language developed, forming the basis of the character of the Valencian people as they are known today.
Who was expelled from Valencia after James I's victory?
---
Answer: the Muslim population

Problem: In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.
What type of risk assessment results in approving the drug to go on the market?
---
Answer:
positive benefit-risk